Triple-negative breast cancer (TNBC) is characterized by poor prognosis and lack of targeted therapies and biomarkers to guide decisions on adjuvant chemotherapy. Parathyroid hormone-related protein (PTHrP) is frequently overexpressed in breast cancer (BC) and involved in proliferation and metastasis, two hallmarks of poor prognosis for node-negative BC. We investigated the prognostic value of PTHrP with respect to organ-specific metastasis and nodal status in TNBC.
Introduction
Triple-negative breast cancers (TNBCs), defined by absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) represent 15-20% of all BC cases and are characterized by aggressive clinical course, increased rate of metastases and lack of targeted therapy [1] [2] [3] . Several clinico-pathologic variables have been shown to significantly affect patient outcome in TNBC, including tumor size, lymph node status, tumor grade, age at diagnosis, and type of surgery and chemotherapy [4, 5] . Nodal status represents an important prognostic factor for adjuvant chemotherapy decision-making for women with node-positive BC and high-risk women with node-negative BC [6] . Therapeutic decisions for node-negative BC are mostly guided using clinico-pathologic risk classifications such as age, tumor grade, LVI, and tumor size [7, 8] . Novel prognostic biomarkers are required for the identification of node-negative TNBC patients at high risk of distant metastasis and death [9] .
Parathyroid hormone-related protein (PTHrP), ubiquitously expressed in normal adult and fetal tissues is involved in a wide range of developmental processes, including the development of mammary glands [10] [11] [12] . PTHrP also displays growth-promoting and antiapoptotic properties [13] , and is frequently overexpressed in BC and other solid tumors [14] [15] [16] [17] [18] [19] [20] [21] [22] .
Using the MMTV-PyMT mouse model of mammary cancer, we showed that PTHrP is implicated in all stages of BC initiation, progression, and metastasis, where it regulates the expression of key signaling molecules involved in proliferation and metastasis [23] . While increased cell proliferation and propensity for metastasis are key determinants for prognosis of node-negative patients [24, 25] , the prognostic value of PTHrP in TNBC and node-negative disease in particular remains unknown. The purpose of this study was to investigate the clinical significance of PTHrP specifically in TNBC. We identified a subset of 314 patients with available tumor tissue and clinical data in a population-based cohort of treatment-naive patients newly diagnosed with TNBC, previously characterized by our group [26] . We investigated the correlation between immunohistochemical expression of PTHrP and clinical outcomes, including progression, organspecific metastasis, and survival based on lymph node status and adjuvant chemotherapy treatment. Survival prognostic value of PTHrP was validated using a publicly available dataset of The Cancer Genome Atlas (TCGA).
Methods

Study Population
Patients with newly diagnosed TNBC between January 1998 and December 2008 in a single cancer center were included. Immunohistochemical staining for ER, PR, and HER2 was performed centrally and prospectively using standard methods [27, 28] . Patients with neoadjuvant chemotherapy, metastatic BC at presentation, or multiple primary malignancies were excluded. Patients were offered guideline-based staging, surgery, adjuvant chemotherapy, and radiotherapy (Supplementary Methods) as per published recommendations [6, 29, 30] .
Ethics Statement
The Alberta Cancer Research Ethics Committee has waived patient consent (impractical, 
Tissue microarray and Immunohistochemistry
We constructed a tissue microarray (TMA) containing triplicate cores for 523 formalinfixed paraffin-embedded pre-treatment TNBC tissue specimens on 7 paraffin blocks. Cores from normal tissues were incorporated as internal controls. Immunohistochemistry (IHC) staining of PTHrP was optimised for automated IHC, then performed on TMA sections using anti-PTHrP antibody (Santa Cruz, sc20728, 1:10 dilution, Supplementary Methods). A practicing breast pathologist (A.O.) blinded to clinical outcomes performed PTHrP scoring. PTHrP expression in tumor cores was evaluated relative to its expression in normal breast tissue. PTHrP-high refers to tumor tissues with stronger staining than normal breast tissue, and PTHrP-low to tumor tissues with staining equal to or lower than normal breast tissue. The strongest PTHrP staining intensity obtained among tumor cores for the same patient was used for scoring analysis.
Endpoints and Statistical analysis
The variables analyzed included age at diagnosis, tumor size, grade, nodal status, lympho-vascular invasion (LVI), adjuvant chemotherapy, surgery type, and adjuvant radiotherapy. Patients with missing information for tumor grade (2 cases), adjuvant chemotherapy (2 cases) and PTHrP expression (24 cases) were excluded from statistical analysis of these variables. The endpoints of this study were progression-free survival (PFS), central nervous system (CNS)-PFS, brain metastasis-free survival (BMFS) and overall survival (OS).
OS was measured from the date of surgery to the date of death from any cause. Patients last known to be alive were censored at the date of last follow-up. PFS, CNS-PFS and BMFS were measured from the date of surgery to the date of progression, CNS-progression or brain metastasis (BM), respectively. Patients who did not progress (for PFS), or did not experience CNS metastasis (for CNS-PFS), or BM (for BMFS) were censored at either the date of death, or date of last follow-up if they were still alive. Chi-square test and Fisher's exact test were used, when appropriate, to evaluate the association of PTHrP expression with clinico-pathologic characteristics, progression, organ-specific metastasis, and survival. PFS, CNS-PFS, BMFS and OS curves were constructed according to the Kaplan-Meier method. The log-rank test was used to compare patient survival probability between different groups. The median follow-up time for OS was calculated based on the "reverse Kaplan-Meier" method [31] . Cox proportional hazards regression models were used for univariable and multivariable survival analyses. We assessed the assumption of proportional hazards by examining graphs of scaled Schoenfeld residuals.
Only the variables with statistically significant p-value (P≤.05) in univariate analysis were included in the multivariable model. All analyses were two-sided with P≤.05 being considered statistically significant. Statistical analysis was conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).
TCGA data analysis
The breast invasive carcinoma associated datasets containing clinical information and mRNA expression were collected from the Genomic Data Commons (GDC) data portal of 
Results
Patients and treatment characteristics
We analyzed a subset of patients with available tissue specimens from a large cohort of treatment-naive women newly diagnosed with TNBC (n=768) characterized by our group [26] .
This subset (n=314) displayed similar proportions of all clinico-pathologic characteristics analyzed as compared to the entire cohort. In agreement with previous reports [32, 33] [35, 36] , the 5-year OS for this population was 70%.
Median OS following CNS progression was only 3.2 months (range 0-14.3 months).
PTHrP expression in a TMA from a population-based study of patients with TNBC
We assessed for the first time immunohistochemical expression of PTHrP in TNBC. We [37, 38] , PTHrP was mainly localized to the cytoplasm of TNBC tumor cells, whereas stromal regions showed negative PTHrP staining ( Figure 1 ). Staining of TMA internal control cores from various normal tissues (Supplementary Figure 1) showed PTHrP expression levels similar to the "Human Protein Atlas" PTHrP scoring analysis [39, 40] .
PTHrP overexpression is associated with increased rate of CNS metastasis
We next examined the relationship between immunohistochemical PTHrP expression levels and clinico-pathologic characteristics of TNBC patients. PTHrP expression was not significantly correlated with the rate and type of progression of TNBC patients (Supplementary   Table 2 ). However, analysis of distant progression sites revealed a statistically significant association between high PTHrP expression and increased rate of CNS metastasis in all patients (P=.0232) and in patients with distant metastasis (P=.0238) (Figure 2A-B Table 1 ). To gain further insight into the role of PTHrP in BM, we examined gene signatures previously known to be involved in BC metastatic progression to the brain [41] .
Using "Breast Cancer Gene-Expression Miner" microarray-based tool [42] , we conducted in silico analyses of publicly available BC datasets to evaluate the correlation between the expression of the PTHLH gene, which encodes PTHrP, and these gene signatures across several BC subtypes. Interestingly, PTHLH correlates with the BM genes HBEGF (Heparin-binding EGF-like growth factor) and ANGPTL4 (Angiopoietin-like 4) selectively in TNBC and basal-like subtypes (Supplementary Table 2 ) known for their common morphological and genetic features and their increased rate of BM [43] . These data suggest for the first time a correlation between PTHrP expression and CNS metastasis specifically in TNBC. Table 3 ). In multivariable analysis, we analyzed the prognostic association of PTHrP with CNS-PFS and OS when adjusted to the covariates found statistically significant in univariable analysis (Supplementary PTHrP has statistically significant independent prognostic value for CNS-PFS, but not OS.
PTHrP overexpression is significantly associated with poor CNS-PFS and OS in TNBC
PTHrP overexpression is an independent prognostic factor for poor OS in LN-negative TNBC
To minimize the considerable influence of LN positivity on patients' outcome, we analyzed the prognostic value of PTHrP in our cohort based on LN stratification. Indeed, in accordance with other TNBC cohorts [5] , LN status showed a strong statistically significant prognostic value in our population (P<.0001) ( Supplementary Figure 3 ). We found that PTHrP had statistically significant prognostic value for OS only in the LN-negative subgroup using Kaplan-Meier analysis (P=.0272) ( Figure 3A and Supplementary Figure 4 ). Strikingly, high
PTHrP expression emerged as an independent negative prognostic factor for OS (HR=2.423, 95% CI=1.129 to 5.197, P=.0231) in multivariable analysis including co-variates statistically significant in univariable analysis of the LN-negative subpopulation (Table 3) , with a HR comparable to that of LN-positivity (N2) in the whole population ( Table 2) . Treatment with adjuvant chemotherapy was an independent prognostic factor for improved OS (HR=0.285, 95%
CI=0.111 to 0.733, P=.0091) in node-negative disease ( Table 3 ). These results indicate that PTHrP independently predicts OS in LN-negative TNBC.
PTHrP expression is the only statistically significant prognostic factor for OS in LN-
negative TNBC patients with low-clinical risk
Clinico-pathologic risk factors including age, tumor grade, LVI, and tumor size are mostly used to inform therapeutic decisions in node-negative BC [7] . Accordingly, analysis of the association between adjuvant chemotherapy and clinico-pathologic parameters of LNnegative patients in our cohort recapitulates these standard clinical risk stratification criteria (Supplementary Table 5 ). Patients who did not receive adjuvant chemotherapy are referred to as low-clinical risk, and those who did as high-clinical risk patients.
Since PTHrP overexpression is an independent predictor of OS in the LN-negative subgroup, we sought to investigate its prognostic value based on adjuvant chemotherapy treatment. We found that PTHrP was a statistically significant prognostic factor selectively in the low-clinical risk subgroup (P=.0387) ( Figure 3B-C) , where it is the only statistically significant factor for OS (HR=2.576, 95% CI=1.019 to 6.513, P=.0456) ( Supplementary Table 6 ).
Collectively, these data suggest that LN-negative patients with low-clinical risk who have high
PTHrP expression and poor OS should have been eligible for adjuvant chemotherapy. Hence, PTHrP IHC scoring analysis could be potentially added to standard clinico-pathologic criteria to select newly diagnosed LN-negative TNBC patients for adjuvant chemotherapy.
Discussion
We investigated the clinical significance of PTHrP in TNBC using immunohistochemical analysis of PTHrP expression in a TMA constructed from archived primary tumors of patients newly diagnosed with TNBC. In this population-based study, while PTHrP was not significantly correlated to PFS, we uncovered for the first time a statistically significant association between high PTHrP expression and increased rate of CNS metastasis in TNBC patients. Remarkably, PTHrP overexpression emerged as a statistically significant independent negative prognostic factor for CNS-PFS.
Interestingly, our analysis of transcriptomic data from bc-GenExMiner correlating gene expression with BC molecular subtypes showed a statistically significant positive correlation between PTHLH and TGF-1 specifically in TNBC and between PTHLH and ANGPTL4 specifically in TNBC and basal-like subtypes (Supplementary Table 2 ). A previous study showed that the brain metastatic TNBC cell line MDA-231BR increased PTHrP production in response to TGF-β1 compared to the parental MDA-MB-231 cell line [44] . ANGPTL4 is known to promote BC cells extravasation through the non-fenestrated capillaries of the brain and lungs [45] [46] [47] . Furthermore, TGF-β1 has been shown to induce ANGPTL4 in breast cancer cells, which disrupts vascular endothelial junctions and promotes metastasis [46] . The relationship identified in our in silico analysis between PTHLH and TGF-β1 and between PTHLH and ANGPTL4 specifically in TNBC could be related to the tumor-suppressive function of microRNA-520/373 family in ER-negative BC, wherein miR-520c expression was inversely correlated to LN metastasis in ER-negative, but not ER-positive tumors and miR-520/373 mediated direct suppression of TGFBR2 and decreased expression of Smad-dependent tumorpromoting genes, including PTHLH and ANGPTL4 [48] . Additional studies are warranted to provide mechanistic insights into the potential context-specific TGF-β-mediated regulation of PTHrP and ANGPTL4 to promote brain metastasis in TNBC.
The association between BM and decreased survival in TNBC [49] highlights the need to elucidate the mechanisms underlying BM in TNBC [43, 47, 50] and identify new targets to hinder tumor progression to the brain. Our findings, if validated in other cohorts of early stage newly-diagnosed TNBC patients raise the hypothesis that monitoring TNBC patients with high PTHrP expression using brain imaging screening to detect early stages of BM might identify patients with first recurrent BM. This might ultimately increase their benefit from whole-brain radiotherapy, stereotactic radiosurgery, surgical resection, or chemotherapy in combination with novel targeted therapies or immunotherapy [51, 52] .
Intriguingly, while PTHrP has been previously linked to bone metastasis in BC [14, 38, 53 , 54], we did not identify a statistically significant relationship between PTHrP overexpression and increased incidence of bone metastasis in the TNBC study population. This could be attributed to a potential difference between PTHrP expression in the primary tumors of earlystage TNBC patients and bone metastatic sites. Of note, TNBC is known to have the lowest incidence of bone metastasis as compared to other BC subtypes [55] .
Our results demonstrated that PTHrP expression had a statistically significant prognostic value in TNBC, where it was associated with worse OS of patients in univariable analysis. These data are in line with several studies showing that PTHrP expression in BC is correlated with poor patient survival [14, 38, 53, 54, 56] . PTHrP overexpression was an independent negative prognostic factor for OS specifically in the LN-negative subgroup in multivariable analysis,
wherein it increased the risk of death (HR=2.423) to an extent similar to LN-positivity N2 in the whole population (HR=2.970), suggesting potential implications in clinical management of TNBC. Indeed, current prognostic factors fail to accurately identify high-risk node-negative BC patients, and microarray-based biomarkers for adjuvant chemotherapy decisions, including those from the MammaPrint assay are not useful for patients with TNBC [9] . Although previous IHC studies have successfully identified biomarkers with statistically significant prognostic value for predicting recurrence and survival in node-negative BC and TNBC [24, 57] , their findings failed to translate into the clinical setting to tailor patients' treatment and surveillance strategies. Our discovery that a PTHrP biomarker-based test might independently stratify survival of LNnegative patients with low-clinical risk in our cohort suggests its potential clinical utility to inform decisions on adjuvant systemic chemotherapy in node-negative TNBC, if confirmed in other independent datasets.
Limitations to our study include its retrospective design, which underscores the need to investigate the predictive value of PTHrP for adjuvant chemotherapy-selection of node-negative patients in a future prospective randomized clinical trial. Our single-cancer institution analysis offers the advantage of standardized diagnostic, treatment and follow-up procedures in a large sample size cohort including only triple-negative subtype. However, we cannot extend our findings to other TNBC cohorts with predominant representation of a specific ethnic/race group [58] . Noteworthy, we validated the prognostic value of PTHrP and its association with CNS metastasis using TCGA and bc-GenExMiner, respectively.
In conclusion, we identified PTHrP as a novel independent prognostic biomarker for CNS metastasis with potential clinical value for adjuvant chemotherapy-selection of nodenegative patients in TNBC. PTHrP, a secreted factor detectable in the serum [15] , could be used to non-invasively investigate therapeutic monitoring of patients diagnosed with TNBC. Future
PTHrP-targeted strategies might provide an alternative treatment option for this molecularly and clinically distinct group of TNBC. P values ≤ .05 were considered statistically significant. *P ≤ .05; **P ≤ .01; ***P ≤ .001. 
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